Literature DB >> 16802285

The neurobiology of neurooncology.

Tracy-Ann Read1, Balazs Hegedus, Robert Wechsler-Reya, David H Gutmann.   

Abstract

The histological classification of brain tumors currently is based on the morphological appearance and protein expression patterns that reflect specific cell types within the central nervous system. Recent studies have suggested that the cells of origin for brain tumors may persist in the fully formed tumors, and that these "cancer stem cells" might represent the relevant cellular targets for anticancer therapy. In this regard, insights into the developmental neurobiology of brain tumors has significant impact on our understanding of the molecular and cellular pathogenesis of these devastating cancers, as well as the development of new strategies for treating brain tumors.

Entities:  

Mesh:

Year:  2006        PMID: 16802285     DOI: 10.1002/ana.20912

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

Review 1.  The cancer stem cell paradigm: a new understanding of tumor development and treatment.

Authors:  Johnathan D Ebben; Daniel M Treisman; Michael Zorniak; Raman G Kutty; Paul A Clark; John S Kuo
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Marker-independent identification of glioma-initiating cells.

Authors:  Virginie Clément; Denis Marino; Cristina Cudalbu; Marie-France Hamou; Vladimir Mlynarik; Nicolas de Tribolet; Pierre-Yves Dietrich; Rolf Gruetter; Monika E Hegi; Ivan Radovanovic
Journal:  Nat Methods       Date:  2010-02-21       Impact factor: 28.547

Review 3.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

Review 4.  MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme.

Authors:  Pilar González-Gómez; Pilar Sánchez; Helena Mira
Journal:  Mol Neurobiol       Date:  2011-07-05       Impact factor: 5.590

5.  Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.

Authors:  Helena Nord; Susan Pfeifer; Pelle Nilsson; Johanna Sandgren; Svetlana Popova; Bo Strömberg; Irina Alafuzoff; Monica Nistér; Teresita Díaz de Ståhl
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

6.  Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Regia Caroline Lira; Augusto Faria Andrade; Paola Fernanda Fedatto; Gustavo Alencastro Veiga Cruzeiro; Ricardo Bonfim Silva; Aparecida Maria Fontes; Elvis Terci Valera; Michael Bobola; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cytotechnology       Date:  2013-01-17       Impact factor: 2.058

Review 7.  Childhood brain tumors: accomplishments and ongoing challenges.

Authors:  Roger J Packer
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.

Authors:  Tracy-Ann Read; Marie P Fogarty; Shirley L Markant; Roger E McLendon; Zhengzheng Wei; David W Ellison; Phillip G Febbo; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

9.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Authors:  Zeng-Jie Yang; Tammy Ellis; Shirley L Markant; Tracy-Ann Read; Jessica D Kessler; Melissa Bourboulas; Ulrich Schüller; Robert Machold; Gord Fishell; David H Rowitch; Brandon J Wainwright; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

10.  Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.

Authors:  Qian Chu; Brent A Orr; Samantha Semenkow; Eli E Bar; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2013-04-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.